The contract will apply to Highmark’s commercial insurance members in national and Pennsylvania, West Virginia and Delaware markets. Highmark said the contract marks one of the first outcomes-based agreements for a drug treating the chronic lung diseases.
Under the contract, if Highmark members who use Symbicort don’t have aligned results with clinical trials performed by AstraZeneca, the drugmaker will issue Highmark a rebate.
More articles on supply chain:
‘We can’t view ourselves as the box pushers of a hospital’: 3 experts discuss the evolving hospital supply chain
CVS Health elevates Kevin Hourican to president of CVS Pharmacy: 4 things to know
Coastal Meds recalls all drug products marketed as sterile
